TrialThe British journal of dermatology2022

The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study.

Y Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.